Introduction key words endoscopic ultrasound and hemostasis. Human-only articles were selected. The references of pertinent studies were manually searched to identify additional relevant studies. The indication, procedural details, technical and clinical success rate, complications and limitations for each study were reviewed.
Results
Only 13 original articles were considered appropriate to be included in the review article. Out of them, five were case reports from India [Sharma and Somasundaram, 2010; Rana et al. 2011] , the UK [Krystallis et al. 2012 ] and the US [Kinzel et al. 2014; Ribeiro et al. 2001 ]. There were three case series from France [Gonzalez et al. 2012] , Spain [Romero-Castro et al. 2007 ] and the US [Lahoti et al. 2000] . Two retrospective studies (analyzing prospectively maintained databases) from the US [Binmoeller et al. 2011] and Spain [Romero-Castro et al. 2013] ; two retrospective [Law et al. 2014; Bhat et al. 2015] from the US and one prospective study [Seewald et al. 2008] from China were also included in the review. All studies have been summarized in Table 1 .
Indications
Refractory bleeding is described in patients who have undergone first-line endoscopic intervention by upper endoscopy or colonoscopy but later present with overt or occult bleeding. Although the primary treatment modality for esophageal varices has been the banding or the use of beta-blockers, management of gastric, duodenal or rectal varices remains debatable. There is expanding evidence for EUS-assisted technique in achieving hemostasis for patients with refractory bleeding [Sharma et al Sharma and Somasundaram, 2010; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Law et al. 2014] , primary prevention [Rana et al. 2011; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Lee et al. 2000] or secondary treatment of variceal bleeding [Gonzalez et al. 2012; Binmoeller et al. 2011; Romero-Castro et al. 2013; Bhat et al. 2015; Lee et al. 2000] . Two studies reported the use of EUS-assisted hemostasis in the setting of hemorrhagic shock secondary to nonlocalization of the bleeding vessel by routine endoscopic techniques [Sharma and Somasundaram, 2010; Krystallis et al. 2012] . Two authors presented their data on EUS-assisted hemostasis among patients with gastric varices, who either have large varices (>1cm) or have failed or were poor candidates for TIPS [Binmoeller et al. 2011; Romero-Castro et al. 2013] . A study by Law and colleagues reported the utility of EUS in achieving hemostasis in the setting of failed endoscopic therapy, radiological intervention and surgery [Law et al. 2014] .
Site and etiology of gastrointestinal bleed
Both upper and lower GI bleeds are amenable to EUS-assisted hemostasis. Romero-Castro and colleagues reported two case series with 5 and 30 patients respectively, who were managed with EUS for underlying gastric varices [Romero-Castro et al. 2007; 2013] . Similarly, a case series of 30 patients undergoing EUS-assisted procedure for gastric varices (with a mean of 1.3 varices per patient) was reported by Binmoeller and colleagues [Binmoeller et al. 2011] . Two more authors reported their experience in using the EUS-assisted hemostasis technique as the prophylactic or secondary treatment for the gastroesophageal varices (GEV) among 152 and 54 patients respectively [Bhat et al. 2015; Lee et al. 2000 ]. Another study described the use of EUS in managing patients with esophageal varices in a case series of five patients [Lahoti et al. 2000 ].
In a case report, authors described a case of gastric Dieulafoy lesion with recurrent bleeding where EUS was helpful in both diagnosis and management of the lesion [Ribeiro et al. 2001 ]. Authors of another study reported the role of EUS in managing gastric lesions like varices, Dieulafoy lesions and arterial malformations [Gonzalez et al. 2012 ]. Sharma and Somasundaram described a patient with a bleeding rectal varix, controlled with the aid of EUS [Sharma and Somasundaram, 2010] . Three authors reported their experience with EUS-assisted treatment of duodenal varices [Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014 ]. Law and colleagues reported their case-bycase experience in achieving EUS-assisted hemostasis in a variety of lesions, ranging from those of oncogenic etiology like primary esophageal cancer, metastatic duodenal disease, gastric tumors like GI stromal tumors (GIST), prostate cancer eroding into rectum; vascular abnormalities like gastric and duodenal Dieulafoy lesions, aberrant rectal vessels and arteriovenous malformations; to those of miscellaneous etiology like marginal ulcer post Roux-en-Y gastric bypass (RYGB) procedure, pancreatic pseudoaneurysm and Brunner gland hematoma [Law et al. 2014 ].
Source of gastrointestinal bleed
There are multiple case series and case reports describing the efficacy of EUS-assisted hemostasis for venous bleeds [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000] , with minimal data on safety and efficacy of EUS-assisted hemostasis for arterial bleeds [Ribeiro et al. 2001; Law et al. 2014] .
Technique

Echoendoscope
Radial- [Rana et al. 2011; Krystallis et al. 2012] or linear-array [Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015] therapeutic echoendoscopes with color Doppler have been used by most endoscopists for localizing and targeting the feeding vessels.
Puncture needle
Both 19 gauge (G) [Kinzel et al. 2014; Gonzalez et al. 2012; Binmoeller et al. 2011; Romero-Castro et al. 2013; Bhat et al. 2015 ] and 22 G [Kinzel et al. 2014; Romero-Castro et al. 2007 , 2013 Law et al. 2014; Bhat et al. 2015] fine needle aspiration (FNA) needles have been used most frequently for EUS-assisted coiling whereas a 22 G FNA needle has been preferred for EUSassisted injection therapy (sclerosant, glue and desiccants).
Type of intervention
EUS increases endoscopists' ability to better characterize the pathologic vascular lesion. It helps to localize the feeding blood vessel, which can be then targeted specifically. Authors have reported use of EUS-assisted injection therapy [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Law et al. 2014; Lee et al. 2000 ], coiling [Romero-Castro et al. 2013; Law et al. 2014] , banding [Ribeiro et al. 2001; Law et al. 2014] , thermal-contact therapy [Ribeiro et al. 2001 ] and combination therapies like glue injection and coiling [Kinzel et al. 2014; Binmoeller et al. 2011; Bhat et al. 2015] , ethanol injection and band ligation [Law et al. 2014] , or epinephrine injection along with snare ligation and polypectomy [Law et al. 2014] . A lot of diversity has been seen in the agent of use for the EUS-assisted injection therapy, ranging from glue therapy with histoacryl glue for rectal varix [Sharma and Somasundaram, 2010] , N-butyl-2-cyanoacrylate for esophageal cancer [Law et al. 2014 ], gastroesophageal varix [Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lee et al. 2000 ], gastric GIST [Law et al. 2014] , gastroduodenal artery malformation [Gonzalez et al. 2012 ], Dieulafoy lesion [Gonzalez et al. 2012 ], duodenal varix [Rana et al. 2011 ], duodenal ulcer [Law et al. 2014] , and duodenal metastatic disease [Law et al. 2014 ]. 2-octylcyanoacrylate glue has been used successfully for duodenal and gastric varices [Kinzel et al. 2014; Binmoeller et al. 2011] , while desiccants like alcohol have been used for duodenal metastatic disease [Law et al. 2014 ], pancreatic pseudoaneurysm [Law et al. 2014 ], rectum-invading prostate cancer [Law et al. 2014] , and gastric Dieulafoy lesion [Ribeiro et al. 2001 ]. Sclerosants like sodium morrhuate have been used for esophageal varices [Lahoti et al. 2000] , hyaluronate for gastric GIST [Law et al. 2014 ] and thrombin injections for duodenal varices [Krystallis et al. 2012 ]. There is a paucity of trials comparing the efficacy across different modes of EUS-assisted hemostasis. Romero-Castro and colleagues compared the EUS-assisted glue injection therapy against coiling as the method of achieving hemostasis and obliteration of blood flow for gastric varices. The study revealed that EUS-assisted coiling subgroup required fewer endoscopies and tended to have fewer adverse events than the glue-therapy subgroup [Romero-Castro et al. 2013 ].
The quantity of coil or injection agent required alone or in combination to achieve hemostasis is not uniform, as shown in Table 2 . In most studies, the decision was made by the endoscopist, during procedure, based on the size of target lesion and Doppler findings of persistent blood flow after initial intervention [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ]. For large blood vessels, use of two coils has been described [Binmoeller et al. 2011; Romero-Castro et al. 2013; Law et al. 2014; Bhat et al. 2015] . In few cases, the endoscopists have used combination treatment with injection therapy and coils [Kinzel et al. 2014; Binmoeller et al. 2011; Bhat et al. 2015] . The number of required coils varied depending on whether the endoscopist had planned to use it alone [Romero-Castro et al. 2013; Law et al. 2014] or in combination with injection therapy [Kinzel et al. 2014; Binmoeller et al. 2011; Bhat et al. 2015 ] to achieve hemostasis, and the same principle applied for the quantity of injection agent [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ]. Romero-Castro and colleagues reported a wide range for the number of coils (2-13) required per patient to achieve hemostasis in the absence of concomitant injection therapy [Romero-Castro et al. 2013] . The size of coil was determined, based on the size of the target vessel on Doppler ultrasound. Romero-Castro and colleagues reported using a 20% larger-sized coil than the size of the target vessel [Romero-Castro et al. 2013] , similar to that of Law and colleagues who reported using coils, 1.25 times the size of target-vessel diameter. Also, the size of coil has been reported to vary from as small as 6 mm [Law et al. 2014 ] to as large as 20 mm [Binmoeller et al. 2011; Romero-Castro et al. 2013] . The quantity of injection therapy also varies with the type of agent [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ] and has been reported to be as low as 0.2 ml of 99% alcohol [Law et al. 2014] or 0.5 ml of N-butyl-2-cyanoacrylate glue [Bhat et al. 2015] per session, to as high as 4 ml of sodium morrhuate [Lahoti et al. 2000] , 7.5 ml of alcohol [Law et al. 2014] or 10 ml of epinephrine [Law et al. 2014 ]. For the concern of possible pulmonary embolism linked to glue therapy, Romero-Castro and colleagues restricted the amount of injection therapy to 1 ml per session [Romero-Castro et al. 2013 ].
The optimal amount of therapeutic agents for EUS-assisted hemostasis remains debatable and is driven by multiple endoscopic parameters.
Outcome
Hemostasis and obliteration of blood flow
Out of total 306 cases [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013; Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ], 71 cases were reported to have evidence of active bleeding at the time of EUS-assisted index therapeutic procedure. In 93% of the cases (66/71), hemostasis (stoppage of active bleeding) was achieved post procedure. Romero-Castro and colleagues reported obliteration of blood flow in five out of five gastric varices cases (100%) post EUS-assisted glue therapy after a mean of 1.6 sessions [Romero-Castro et al. 2007] . Similarly, complete cessation of blood flow in five out of five esophageal varices cases (100%) was achieved after a mean of 2.2 sessions of EUS-assisted sclerotherapy [Lahoti et al. 2000 ]. In another study, complete obliteration of blood flow in 23/24 gastric varices cases was reported after single session of combination treatment with EUS-assisted coiling and glue therapy, whereas 1/24 cases required two sessions of treatment [Binmoeller et al. 2011 ].
Romero-Castro and colleagues also reported complete cessation of blood flow in 19/19 gastric varices cases post EUS-assisted glue therapy after a mean of 1.5 sessions of treatment, in contrast to 10/11 gastric varices cases post EUS-assisted coiling after a mean of 1.3 sessions of treatment [Romero-Castro et al. 2013] . Out of five case reports, three authors reported complete cessation of blood flow post procedure [Rana et al. 2011; Kinzel et al. 2014; Ribeiro et al. 2001] , one achieved only a decrease in blood flow [Krystallis et al. 2012 ] and one reported no documentation with this respect [Sharma and Somasundaram, 2010] . Law and colleagues reported complete cessation of blood flow in 10/17 patients (58.8%) after a single session of treatment, in 1/17 patients (5.9%) after two sessions of treatment and decrease in blood flow in 5/17 patients (29.4%) after a single session of treatment. In another study, complete cessation of blood flow was achieved after a single treatment session in all except one (7/8) that required a second session [Gonzalez et al. 2012] . Complete obliteration of GEV was achieved in 93/100 (93%) [Bhat et al. 2015] and 43/47 (91.5%) [Lee et al. 2000] patients with EUS-assisted intervention.
Follow up
Most authors report a variable follow up of the patients, ranging from a minimum of 3 weeks to a maximum of 120 months [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ]. After achieving initial hemostasis on index endoscopy, the endoscopist should re-evaluate the patients at shorter follow-up intervals with repeat EUS, until there is documented cessation of blood flow in the underlying feeding vascular supply and thereafter the follow-up interval can be increased and done based on any clinical or laboratory signs of bleeding.
Rebleeding
Out of 306 total patients [Sharma and Somasundaram, 2010; Rana et al. 2011; Krystallis et al. 2012; Kinzel et al. 2014; Ribeiro et al. 2001; Gonzalez et al. 2012; Romero-Castro et al. 2007 , 2013 Lahoti et al. 2000; Binmoeller et al. 2011; Law et al. 2014; Bhat et al. 2015; Lee et al. 2000 ], 48 patients had a repeat episode of GI bleed post procedure. On further evaluation, only 28 patients (9.2%) had a rebleed from either the recurrence of primary etiology or lack of complete obliteration of blood flow from the therapeutic EUS-assisted treatment performed on the index procedure. In one study [Gonzalez et al. 2012] , 1/8 patients (12.5%) experienced a rebleed, whereas in another study, the authors reported rebleeding in 3/17 patients (17.6%) [Law et al. 2014] . In both of these scenarios, the bleeding was from the same primary etiology and the authors were unable to achieve complete cessation of blood flow on index EUS-assisted intervention [Gonzalez et al. 2012; Law et al. 2014 ]. Bhat and colleagues reported rebleeding from the same primary etiology in 10/125 patients (8%). Only 3 out of 93 patients (3.2%) had rebleeding despite complete obliteration of gastric fundal varices (GFV) on index procedure secondary to recurrence of new GFV in the setting of persistent portal hypertension [Bhat et al. 2015] . Only 4/125 (3.2%) patients had rebleeding secondary to extrusion of the coil and glue from the primary lesion [Bhat et al. 2015 ]. Lee and colleagues reported rebleeding in 14/54 patients (25.9%) post EUS-assisted intervention for GFV. Only four patients had early rebleeding within 48 hours of the primary intervention and the rest occurred beyond 48 hours [Lee et al. 2000 ]. Authors reported that complete obliteration of GFV was achieved in 43/54 patients, out of which 10 (23.3%) had documented recurrence of GFV and seven (16.3%) presented with bleeding after a mean follow up of 14.8 + 10 months [Lee et al. 2000 ].
EUS-assisted coiling in the absence of concomitant injection therapy for hemostasis is still in its baby steps.
Summary and future directions EUS-assisted technique to prevent or treat GI bleeding is a safe, minimally invasive and efficacious alternative approach to surgery or interventional radiology in selected patients who fail the standard endoscopic approach. With present techniques and accessories, management of gastric varices with the EUS-assisted approach seems to be a reasonable first-line approach. The technique has a potential role, not only in assisting in diagnosis by more accurate visualization of the bleeding vascular anomaly but also helps in targeted-injection therapy or placement of coil in the feeding vessels and finally in documenting the obliteration of flow in the bleeding vessel with help of the Doppler technique, resulting in decreased risk of rebleeding. Preliminary reports appear promising, but large multicentric prospective studies are needed in the future to adopt it as a standard alternative therapy for refractory GI bleeding and as primary treatment for gastric varices. With further experience and development of more sophisticated accessories, the arena of EUS-assisted hemostasis is likely to expand across different kinds of GI vascular lesions.
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